Abstract
Hereditary angioedema (HAE) attacks are associated with a prodrome in ∼ 85% of patients’ pre-attack. The purpose of this study was to determine whether blood transcriptomic changes, pre- and post-treatment of a prodrome with Ruconest® (recombinant human C1-INH), overlapped with changes pre- and post-treatment of an acute attack.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
